Altered oncomodules underlie chromatin regulatory factors driver mutations
Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several so...
Gespeichert in:
Veröffentlicht in: | Oncotarget 2016-05, Vol.7 (21), p.30748-30759 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 30759 |
---|---|
container_issue | 21 |
container_start_page | 30748 |
container_title | Oncotarget |
container_volume | 7 |
creator | Frigola, Joan Iturbide, Ane Lopez-Bigas, Nuria Peiro, Sandra Gonzalez-Perez, Abel |
description | Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs. |
doi_str_mv | 10.18632/oncotarget.8752 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5058714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1816630517</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</originalsourceid><addsrcrecordid>eNpVUU1PwzAMjRAIprE7J9Qjl418OU0vSBPiU0hc4BxlqTuK2mYkKdL-Pd0YAyxZtmW_Z1uPkDNGZ0wrwS9953yyYYlppnPgB2TECllMOYA4_JOfkEmM73QwkLnmxTE54TktAHIYkcd5kzBgmW3IWl_2Dcas70oMTY2Zewu-tanusoDLvrHJh3VWWTfEmJWh_sSQtX0aJnwXT8lRZZuIk10ck9fbm5fr--nT893D9fxp6qTQaaqYkhItQ6y4BAEFp5UCYJxJISgtC2FtoRwvdEm5ruhCW6dAisXCAi2dE2Ny9c276hctlg67FGxjVqFubVgbb2vzv9PVb2bpPw1Q0PmwZUzYN4GLvTMBHQZn0xa4LzbOac6NYBK4GjAXu6XBf_QYk2nr6LBpbIe-j4ZpppSgwPJhlO7og48xYLU_jVGzVc78Kmc2yg2Q878v7QE_OokvMoKY9A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1816630517</pqid></control><display><type>article</type><title>Altered oncomodules underlie chromatin regulatory factors driver mutations</title><source>MEDLINE</source><source>PubMed Central Open Access</source><source>Recercat</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Frigola, Joan ; Iturbide, Ane ; Lopez-Bigas, Nuria ; Peiro, Sandra ; Gonzalez-Perez, Abel</creator><creatorcontrib>Frigola, Joan ; Iturbide, Ane ; Lopez-Bigas, Nuria ; Peiro, Sandra ; Gonzalez-Perez, Abel</creatorcontrib><description>Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.8752</identifier><identifier>PMID: 27095575</identifier><language>eng</language><publisher>United States: Impact Journals</publisher><subject>Carcinogenesis - genetics ; Chromatin - metabolism ; Computational Biology ; Càncer ; Datasets as Topic ; DNA-Binding Proteins - genetics ; Gene Expression Profiling - methods ; Gene Expression Regulation, Neoplastic ; Genomics - methods ; Genètica ; Humans ; Mutation ; Neoplasm Proteins - genetics ; Neoplasms - genetics ; Oncogenes - genetics ; Oncologia ; Research Paper ; Signal Transduction - genetics ; TOR Serine-Threonine Kinases - antagonists & inhibitors ; TOR Serine-Threonine Kinases - metabolism</subject><ispartof>Oncotarget, 2016-05, Vol.7 (21), p.30748-30759</ispartof><rights>Copyright @ 2016 Impact Journals, LLC. All site content, except where otherwise noted, is licensed under a https://creativecommons.org/licenses/by/3.0/ https://creativecommons.org/licenses/by/3.0/ info:eu-repo/semantics/openAccess</rights><rights>Copyright: © 2016 Frigola et al. 2016</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</citedby><cites>FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058714/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058714/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,26974,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27095575$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frigola, Joan</creatorcontrib><creatorcontrib>Iturbide, Ane</creatorcontrib><creatorcontrib>Lopez-Bigas, Nuria</creatorcontrib><creatorcontrib>Peiro, Sandra</creatorcontrib><creatorcontrib>Gonzalez-Perez, Abel</creatorcontrib><title>Altered oncomodules underlie chromatin regulatory factors driver mutations</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.</description><subject>Carcinogenesis - genetics</subject><subject>Chromatin - metabolism</subject><subject>Computational Biology</subject><subject>Càncer</subject><subject>Datasets as Topic</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Gene Expression Profiling - methods</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Genomics - methods</subject><subject>Genètica</subject><subject>Humans</subject><subject>Mutation</subject><subject>Neoplasm Proteins - genetics</subject><subject>Neoplasms - genetics</subject><subject>Oncogenes - genetics</subject><subject>Oncologia</subject><subject>Research Paper</subject><subject>Signal Transduction - genetics</subject><subject>TOR Serine-Threonine Kinases - antagonists & inhibitors</subject><subject>TOR Serine-Threonine Kinases - metabolism</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>XX2</sourceid><recordid>eNpVUU1PwzAMjRAIprE7J9Qjl418OU0vSBPiU0hc4BxlqTuK2mYkKdL-Pd0YAyxZtmW_Z1uPkDNGZ0wrwS9953yyYYlppnPgB2TECllMOYA4_JOfkEmM73QwkLnmxTE54TktAHIYkcd5kzBgmW3IWl_2Dcas70oMTY2Zewu-tanusoDLvrHJh3VWWTfEmJWh_sSQtX0aJnwXT8lRZZuIk10ck9fbm5fr--nT893D9fxp6qTQaaqYkhItQ6y4BAEFp5UCYJxJISgtC2FtoRwvdEm5ruhCW6dAisXCAi2dE2Ny9c276hctlg67FGxjVqFubVgbb2vzv9PVb2bpPw1Q0PmwZUzYN4GLvTMBHQZn0xa4LzbOac6NYBK4GjAXu6XBf_QYk2nr6LBpbIe-j4ZpppSgwPJhlO7og48xYLU_jVGzVc78Kmc2yg2Q878v7QE_OokvMoKY9A</recordid><startdate>20160524</startdate><enddate>20160524</enddate><creator>Frigola, Joan</creator><creator>Iturbide, Ane</creator><creator>Lopez-Bigas, Nuria</creator><creator>Peiro, Sandra</creator><creator>Gonzalez-Perez, Abel</creator><general>Impact Journals</general><general>Impact Journals LLC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>XX2</scope><scope>5PM</scope></search><sort><creationdate>20160524</creationdate><title>Altered oncomodules underlie chromatin regulatory factors driver mutations</title><author>Frigola, Joan ; Iturbide, Ane ; Lopez-Bigas, Nuria ; Peiro, Sandra ; Gonzalez-Perez, Abel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-61644ea1eef24535920f65512143300d93aa96c298d028f0b8ac6543bba50dcc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Carcinogenesis - genetics</topic><topic>Chromatin - metabolism</topic><topic>Computational Biology</topic><topic>Càncer</topic><topic>Datasets as Topic</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Gene Expression Profiling - methods</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Genomics - methods</topic><topic>Genètica</topic><topic>Humans</topic><topic>Mutation</topic><topic>Neoplasm Proteins - genetics</topic><topic>Neoplasms - genetics</topic><topic>Oncogenes - genetics</topic><topic>Oncologia</topic><topic>Research Paper</topic><topic>Signal Transduction - genetics</topic><topic>TOR Serine-Threonine Kinases - antagonists & inhibitors</topic><topic>TOR Serine-Threonine Kinases - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Frigola, Joan</creatorcontrib><creatorcontrib>Iturbide, Ane</creatorcontrib><creatorcontrib>Lopez-Bigas, Nuria</creatorcontrib><creatorcontrib>Peiro, Sandra</creatorcontrib><creatorcontrib>Gonzalez-Perez, Abel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Recercat</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frigola, Joan</au><au>Iturbide, Ane</au><au>Lopez-Bigas, Nuria</au><au>Peiro, Sandra</au><au>Gonzalez-Perez, Abel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Altered oncomodules underlie chromatin regulatory factors driver mutations</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2016-05-24</date><risdate>2016</risdate><volume>7</volume><issue>21</issue><spage>30748</spage><epage>30759</epage><pages>30748-30759</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Chromatin regulatory factors (CRFs), are known to be involved in tumorigenesis in several cancer types. Nevertheless, the molecular mechanisms through which driver alterations of CRFs cause tumorigenesis remain unknown. Here, we developed a CRFs Oncomodules Discovery approach, which mines several sources of cancer genomics and perturbaomics data. The approach prioritizes sets of genes significantly miss-regulated in primary tumors (oncomodules) bearing mutations of driver CRFs. We applied the approach to eleven TCGA tumor cohorts and uncovered oncomodules potentially associated to mutations of five driver CRFs in three cancer types. Our results revealed, for example, the potential involvement of the mTOR pathway in the development of tumors with loss-of-function mutations of MLL2 in head and neck squamous cell carcinomas. The experimental validation that MLL2 loss-of-function increases the sensitivity of cancer cell lines to mTOR inhibition lends further support to the validity of our approach. The potential oncogenic modules detected by our approach may guide experiments proposing ways to indirectly target driver mutations of CRFs.</abstract><cop>United States</cop><pub>Impact Journals</pub><pmid>27095575</pmid><doi>10.18632/oncotarget.8752</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1949-2553 |
ispartof | Oncotarget, 2016-05, Vol.7 (21), p.30748-30759 |
issn | 1949-2553 1949-2553 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5058714 |
source | MEDLINE; PubMed Central Open Access; Recercat; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
subjects | Carcinogenesis - genetics Chromatin - metabolism Computational Biology Càncer Datasets as Topic DNA-Binding Proteins - genetics Gene Expression Profiling - methods Gene Expression Regulation, Neoplastic Genomics - methods Genètica Humans Mutation Neoplasm Proteins - genetics Neoplasms - genetics Oncogenes - genetics Oncologia Research Paper Signal Transduction - genetics TOR Serine-Threonine Kinases - antagonists & inhibitors TOR Serine-Threonine Kinases - metabolism |
title | Altered oncomodules underlie chromatin regulatory factors driver mutations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T21%3A27%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Altered%20oncomodules%20underlie%20chromatin%20regulatory%20factors%20driver%20mutations&rft.jtitle=Oncotarget&rft.au=Frigola,%20Joan&rft.date=2016-05-24&rft.volume=7&rft.issue=21&rft.spage=30748&rft.epage=30759&rft.pages=30748-30759&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.8752&rft_dat=%3Cproquest_pubme%3E1816630517%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1816630517&rft_id=info:pmid/27095575&rfr_iscdi=true |